Optimizing vaccine production: comparing serum-free and serum-supplemented media

From cost reduction and security of supply to ease of regulatory approval, the reduction of serum is an increasingly important consideration for vaccine developers. However, as the majority of vaccine development cell lines are adherent, many developers may not consider eliminating serum during the early growth stages. From transitioning cells to suspension, to using innovative serum-free media that have been optimized for adherent cell lines, there are several ways vaccine developers can re-evaluate and reduce their serum usage. This eBook presents case study data comparing growth in serum-supplemented, serum-free, and serum-reduced media with four popular vaccine development cell lines—Vero, MDCK, MRC-5, and HEK293.

Please enter your email to access content Read now